Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 31, 2023

Patritumab Deruxtecan, a HER3-Directed Antibody–Drug Conjugate, for Heavily Pretreated HER3-Expressing Metastatic Breast Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
J. Clin. Oncol 2023 Oct 06;[EPub Ahead of Print], IE Krop, N Masuda, T Mukohara, S Takahashi, T Nakayama, K Inoue, H Iwata, Y Yamamoto, RH Alvarez, T Toyama, M Takahashi, A Osaki, S Saji, Y Sagara, J O'Shaughnessy, S Ohwada, K Koyama, T Inoue, L Li, P Patel, J Mostillo, Y Tanaka, DW Sternberg, D Sellami, K Yonemori

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading